NICE has said EUSA Pharma’s Qarziba for the rare childhood cancer high-risk neuroblastoma should not get regular funding from the NHS – but could be given interim funding on the Cancer Drugs Fund following a price cut. The cost-effectiveness body ...
Original Article: NICE asks EUSA pharma to drop price of neuroblastoma drug